Ipv clinical trials

Explore recruiting ipv clinical trials.

Recruiting ipv studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ipv trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 4, randomised vaccination study in healthy adults to investigate the effects of acellular pertussis vaccine on colonisation with Bordetella pertussis using controlled human infection (KIM-study)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

EFFICACY OF VASOCONSTRICTOR PERIARTICULAR INFILTRATION (PIV) VERSUS ERECTOR SPINAE PLANE BLOCK (ESP) IN REDUCING BLEEDING AND POSTOPERATIVE PAIN CONTROL IN LUMBAR ARTHRODESIS SURGERY. RANDOMIZED CLINICAL TRIAL.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine when Administered to Healthy Infants

Poland, Spain, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

Bulgaria, Poland, Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Ipv trials by city

Ipv in Toronto Ipv in Vancouver Ipv in Montreal Ipv in Calgary Ipv in Edmonton Ipv in Ottawa Ipv in Winnipeg Ipv in Quebec City Ipv in Hamilton Ipv in Kitchener Ipv in London Ipv in Halifax Ipv in New York Ipv in Los Angeles Ipv in Chicago Ipv in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease